Movement Disorders Publication

Cavalon and its collaborators have discovered in an analysis of a major Michael J. Fox Foundation-funded Phase II clinical trial in Parkinson’s disease that patients taking an optimized dose of a candidate drug and who are not limited by a mechanism-based side effect had a significant reduction in Parkinson’s disease progression.